FindTrial
Sign In

Experimental clinical open study, randomized, experimental group vs control group, for the evaluation of tolerability and the effects on magnetic resonance parameters and cognitive functions of memantine in patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta. - NEMESI-MS Neuroprotection by Memantine at Early Stage In Multiple Sclerosis

Experimental clinical open study, randomized, experimental group vs control group, for the evaluation of tolerability and the effects on magnetic resonance parameters and cognitive functions of memantine in patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta. - NEMESI-MS Neuroprotection by Memantine at Early Stage In Multiple Sclerosis

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-000503-15-IT
Enrollment
Unknown
Registered
2007-04-20
Start date
2007-02-19
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients at early stage of relapsing- remitting multiple sclerosis treated with interferon-beta. MedDRA version: 9.1 Level: LLT Classification code 10028245 Term: Multiple sclerosis

Interventions

Trade Name: EBIXA Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Memantine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-

Sponsors

AZ. OSPEDALIERA GARIBALDI, S.LUIGI CURRO , ASCOLI TOMASELLI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Onset of IFN-beta treatment within 3 months Diagnosis of clinically defined Multiple Sclerosis within 2 years according to McDonald s criteria Aged between 18 and 50 years EDSS 8804;3.5 Free from corticosteroids since at least 60 days, from immunosuppressors since at least 6 months and free of other immunomodulators since at least 2 months prior to enrollmentPatients willing to sign informed consent Patients with Beck Depression score 8804;10 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Pregnant, breast-feeding women or those planning pregnancy Primary or secondary epilepsy Serious psychiatric pathologies Alcohol or drug abuse Serious systemic diseases with particular reference to endocrinopathies and metabolic diseases Brain trauma with sequels Depression evaluated according to Beck s scale score 10 Serious impairment and disablement that can interfere with performance of tests

Design outcomes

Primary

MeasureTime frame
Main Objective: To evaluate treatment effects on MRI parameters more directly related to irreversible neurological damage; To evaluate the effects of the therapy on the cognitive sphere.;Secondary Objective: To evaluate the tolerability of a treatment with memantine 10 mg b.i.d. in patients treated with IFN-beta. To evaluate treatment effects on other MRI parameters more directly related to the inflammatory activity of the disease;Primary end point(s): Percentage of reduction in whole brain volume. Percentage of reduction in regional brain volume. Number and volume of new T1 lesions black holes—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026